SAN DIEGO / Aug 08, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received... Read More

SAN DIEGO / Jul 24, 2025 / Business Wire / Revelation Biosciences, Inc. (Nasdaq: REVB) the “Company” or “Revelation”) a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. “George was the chairman of the board of our company,... Read More

Sample analysis and data collection ongoing Data expected during Q3 2025 SAN DIEGO / Jul 16, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME ( PR econditioning IM munostimulatory E valuation) Phase 1b clinical study of... Read More

SAN DIEGO / Jul 01, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company’s common stock will... Read More

SAN DIEGO / May 29, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of... Read More

SAN DIEGO / May 29, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an... Read More

SAN DIEGO / May 23, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company’s Board of Directors. “The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5... Read More

SAN DIEGO / May 08, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated... Read More

This new indication is another step to unlock the full potential of the Gemini Platform SAN DIEGO / Apr 29, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced a new target indication for Gemini for the prevention of infection in severe burn patients requiring... Read More

Observed response is excellent surrogate of the potential of Gemini in target indications Equivalent response anticipated in Phase 1b study CKD patients SAN DIEGO / Mar 17, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused... Read More

SAN DIEGO / Mar 13, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37 th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.... Read More

SAN DIEGO / Mar 06, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients... Read More

Topline data expected Mid-Year SAN DIEGO / Feb 26, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME ( PR econditioning IM munostimulatory E valuation) Phase 1b clinical study of intravenous single ascending doses of Gemini... Read More

SAN DIEGO / Feb 24, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC (“Nasdaq”) formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all... Read More

SAN DIEGO / Jan 24, 2025 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company’s common... Read More

Dosing to Commence Mid-February Topline data expected Mid-Year SAN DIEGO / Jan 21, 2025 / Business Wire / Revelation Biosciences, Inc. ( NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME ( PR econditioning IM munostimulatory E valuation) Phase 1b clinical... Read More

A vote for Proposal 2 saves the Company over $200,000 per year SAN DIEGO / Jan 13, 2025 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders . In... Read More

SAN DIEGO / Dec 03, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common... Read More

Phase 1b Study in CKD Patients to begin early 2025 SAN DIEGO / Dec 02, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND)... Read More

SAN DIEGO / Nov 12, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant... Read More

SAN DIEGO / Nov 08, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial... Read More

SAN DIEGO / Sep 24, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent... Read More

SAN DIEGO / Aug 21, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock,... Read More

SAN DIEGO / Aug 09, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results.... Read More

Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity Gemini was safe and well tolerated at pharmacologically active doses Phase 1 results enable further development across multiple indications SAN DIEGO / Jun 24, 2024 / Business Wire / Revelation Biosciences, Inc.... Read More

Top-line data forthcoming SAN DIEGO / Jun 13, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was... Read More

SAN DIEGO / May 10, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash... Read More

SAN DIEGO / Mar 22, 2024 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Corporate Highlights Completed a $6.2 million public offering. Commencement of... Read More

Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI) SAN DIEGO / Mar 13, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention... Read More

SAN DIEGO / Mar 12, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19,... Read More

Top-line data including safety, tolerability, and biomarker activity anticipated this summer This Phase 1 clinical study data will support further development across multiple indications SAN DIEGO / Mar 04, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and... Read More

Oral presentation in addition to poster presentation announced January 30, 2024 SAN DIEGO / Feb 13, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of... Read More

SAN DIEGO / Feb 05, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on February 5, 2024 of its previously announced public offering of 128,470 shares of its common stock and 1,236,530 pre-funded warrants to purchase... Read More

SAN DIEGO / Feb 01, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of... Read More

Abstract Includes Positive Data from a Recently Completed Preclinical Ischemia Reperfusion Acute Kidney Injury Model SAN DIEGO / Jan 30, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on... Read More

SAN DIEGO / Jan 23, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2024. The reverse stock split will be effective as of the morning of January 25, 2024, and the Company’s common... Read More

SAN DIEGO / Nov 13, 2023 / Business Wire / Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results. Corporate Highlights Recently released biomarker data demonstrating the pharmacologic activity... Read More

Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study SAN DIEGO / Oct 12, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as... Read More

SAN DIEGO / Oct 04, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming 2023 ROTH Healthcare Opportunities Conference being held in New York, NY on October... Read More

SAN DIEGO / Oct 02, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company’s Board of Directors (Board). “We are excited to welcome Dr. Chawla as an independent director to our... Read More

SAN DIEGO / Aug 11, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash... Read More

SAN DIEGO / Jun 29, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders (the “Annual Meeting”) is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges... Read More

SAN DIEGO / Jun 12, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 9, 2023, to July 7,... Read More

SAN DIEGO / May 22, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted recent corporate progress. Corporate Highlights Established strong scientific advisory... Read More

SAN DIEGO / Mar 30, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its year end 2022 financial results and highlighted recent corporate progress. Corporate Highlights Completed a $15.6 million public offering. Announced... Read More

SAN DIEGO / Mar 13, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the... Read More

SAN DIEGO / Mar 06, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held... Read More

SAN DIEGO / Feb 13, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced the closing on February 13, 2023 of its previously announced public offering of 2,888,600 shares of its common stock and 336,400 pre-funded... Read More

SAN DIEGO / Feb 09, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 3,225,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up... Read More

SAN DIEGO / Feb 07, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease. This mechanistic biomarker data further supports the potential clinical utility of REVTx-300 previously announced on November 18, 2022. In this validated preclinical model, administration of... Read More

SAN DIEGO / Jan 31, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company’s common stock... Read More

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 13, 2023, the Company’s units, which trade with the ticker symbol “REVBU” will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company’s common stock and one warrant that entitles the holder to purchase one share of common stock at... Read More

SAN DIEGO, Calif.--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the treatment of CKD and AKI. This new biomarker... Read More